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Abstract
Author Manuscript

Parkinson’s disease (PD) is the second most common neurodegenerative disease worldwide,
caused by the degeneration of the dopaminergic neurons in the substantia nigra. Mutations in
PARK7 (DJ-1) result in early onset autosomal recessive PD, and oxidative modification of DJ-1
has been reported to regulate the protective activity of DJ-1 in vitro. Glutathionylation is a
prevalent redox modification of proteins resulting from the disulfide adduction of the glutathione
moiety to a reactive cysteine-SH; and glutathionylation of specific proteins has been implicated in
regulation of cell viability. Glutaredoxin 1 (Grx1) is the principal deglutathionylating enzyme
within cells, and it has been reported to mediate protection of dopaminergic neurons in C. elegans,
however many of the functional downstream targets of Grx1 in vivo remain unknown. Previously,
DJ-1 protein content was shown to decrease concomitantly with diminution of Grx1 protein
content in cell culture of model neurons (SH-SY5Y and Neuro-2A lines). In the current study we
aimed to investigate the regulation of DJ-1 by Grx1 in vivo and characterize its glutathionylation
in vitro. Here, with Grx−/− mice we provide evidence that Grx1 regulates protein levels of DJ-1 in
vivo. Furthermore, with model neuronal cells (SH-SY5Y) we observed decreased DJ-1 protein
content in response to treatment with known glutathionylating agents; and with isolated DJ-1 we
identified two distinct sites of glutathionylation. Finally, we found that overexpression of DJ-1 in

Author Manuscript

*

To whom correspondence should be addressed. jjm5@case.edu (J.J.M.); shu.chen@case.edu (S.G.C.).
Conflict of Interest statement: None declared

Supporting Information Available
Supplemental items of data include western blot and qPCR analyses for Grx1−/− and hGrx1-transgenic mice, western blot analyses of
human samples, validation of purity and specificity of antibodies, HPLC-mass spectrometric chromatograms, fluorescence data for
quantification of expression of exogenous DJ-1 in C. elegans, and cell culture data for individual components of the proteolytic
inhibitor cocktail. This material is available free of charge via the Internet at http://pubs.acs.org

Johnson et al.

Page 2

Author Manuscript

the dopaminergic neurons partly compensates for the loss of the Grx1 homolog in a C. elegans in
vivo model of PD. Therefore; our results reveal a novel redox modification of DJ-1 and suggest a
novel regulatory mechanism for DJ-1 content in vivo.

Graphical Abstract

Author Manuscript
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Introduction

Author Manuscript

Parkinson’s disease (PD) is a debilitating neurodegenerative disease caused by the loss of
dopaminergic neurons in the substantia nigra region of the midbrain [1, 2]. Although the
etiology of PD is unclear, PD can be categorized into two groups: familial and sporadic.
These classifications are based on whether PD is attributed to a genetic mutation or if the
cause of the disease is undefined. In both cases oxidative stress and dysregulation of redox
homeostasis have been implicated.

Author Manuscript

LRRK2 (Leucine-Rich Repeat Kinase 2) and DJ-1 (PARK7) are two proteins in which
genetic mutations are linked to development of PD [3, 4]. Mutations in LRRK2 are shown to
cause autosomal dominant PD in humans, and over-expression of mutant LRRK2 results in
dysfunction of dopamine signaling or degeneration of dopaminergic neurons in animal
models of PD [5, 6, 7, 8, 9]. Mutations in DJ-1 result in autosomal recessive, early onset PD
in humans, through destabilization and loss of DJ-1 protein content [10]. In addition to
mutations driving familial PD, post mortem brain samples from patients with sporadic PD
have been reported to have decreased levels of DJ-1 protein within several areas of the brain
including the nigral region [ 11]. Although studies have implicated DJ-1 as an anti-oxidant
factor [12, 13], the molecular mechanism(s) by which DJ-1 protects cells from oxidative
stress-induced death is currently unresolved [14]. Genetic manipulation has revealed a key
residue on DJ-1, which is critical for the protection against oxidative stressors. Substitution
of cysteine 106 with alanine (C106A) results in a “non-functional” DJ-1; over-expression of
WT, but not C106A DJ-1, protects Park7−/− mouse embryonic fibroblasts from H2O2induced cell death [15]. In addition, it has been found that cysteine 106 can be oxidatively
modified to the sulfinic acid. This modification has been reported to play a critical role in
protecting M17 neuroblastoma cells from MPP+ toxicity [ 16]. These data suggest that
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sufficient levels of DJ-1 protein and specific redox modification of DJ-1 play important roles
in mediating neuronal protection.

Author Manuscript

Protein S-glutathionylation (Protein-SSG) is a prevalent oxidative modification involving the
formation of a disulfide bond between glutathione (GSH) and a reactive protein-cysteine-SH
[ 2]. Protein glutathionylation can result in changes in subcellular localization, protein
function and/or protein levels [17, 18, 19]. Glutaredoxin 1 (Grx1) is the principal
deglutathionylating enzyme in the cell, restoring the protein-SH and its function [2]. Grx1
has been shown to mediate neuronal protection both in vitro and in vivo [19, 20, 21, 22]. We
recently reported evidence that PD patients have diminished levels of Grx1 specifically
within the remaining dopaminergic neurons of the midbrain compared to controls [20].
Further we found that Caenorhabditis elegans (C. elegans) lacking the homolog of Grx1
displayed exacerbated losses of dopamine-dependent behavior and dopaminergic neurons in
models of both familial and sporadic PD [20]. Thus, it appears that Grx1 mediates protection
of dopaminergic neurons in vitro and in vivo, however the downstream molecular
mechanism(s) that accomplish this protection remain to be elucidated. In this regard,
knockdown of Grx1 in model dopaminergic neurons was previously reported to increase cell
death [21, 22], and to decrease DJ-1 protein content [22]. Over-expression of WT, but not
C53S or C106S DJ-1, abolished the cell toxicity associated with diminished Grx1 function,
suggesting that the content of DJ-1, its cysteine redox status, and its effect on neuronal cell
viability are regulated via Grx1 [22]. Since this interpretation may also apply to our
observations that loss of the Grx1 homolog in C. elegans exacerbates PD-like phenotypes
[ 20], we set out in the current study to determine whether Grx1 regulates DJ -1 in vivo.

Author Manuscript

Here, we report evidence supporting a post-translational mechanism for regulation of DJ-1
protein content involving reversible glutathionylation and regulation by Grx1 in vivo.
Accordingly, over-expression of DJ-1 partially compensates for neuronal toxicity due to the
loss of Grx1 in models of PD.

Methods
Western blot analysis of mouse brain tissue

Author Manuscript

Mouse brain tissues from two independent cohorts obtained from Case Western Reserve
University and The University of Vermont (a kind gift from Dr. Y. Janssen-Heininger), were
dissected into three sections, midbrain, cortex and cerebellum. Midbrain portions of the
brains were snap frozen in liquid nitrogen. Prior to use, midbrains were homogenized by
physical disruption using a pestle in a 1.5 ml Eppendorf tube with Cell Lysis Buffer (Cell
Signaling) containing protease inhibitors (Roche). Tubes were incubated on ice for 15 min
followed by sonication three times for 5 sec each. Samples were clarified by centrifugation
at 4°C for 30 min at 16,000 x g. Aliquots of the supernatant (70 μg of protein content) were
run on a 15% SDS-PAGE gel, transferred to PVDF membrane using a semi-dry transfer
apparatus (Bio-Rad) at 20 V for 1 h, blocked with 5% milk in Tris-buffered saline with
0.05% Tween-20 (TBST) for 1 h, and probed overnight with anti-actin (Sigma, diluted
1:5000), DJ-1 (Abcam,1:5000) and Grx1 (Genscript, 1:1000) antibodies. Blots were washed
three times for 10 min each in TBST and probed with secondary antibodies (Bio-Rad,
1:5000) for 1 h. Blots were developed using enhanced chemiluminescence (Thermo Fisher).
Biochemistry. Author manuscript; available in PMC 2016 August 16.
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Rabbit polyclonal anti-Grx1 was generated by Genscript against recombinant human Grx1
produced in E. coli [ 20]. The western blots were scanned and band densities were quantified
using ImageJ software (NIH).
Western blot analysis of human brain tissue

Author Manuscript

Postmortem brain tissue samples from histopathologically diagnosed PD and non-PD cases
(Supplemental Table A), were used for this study according to approved IRB protocols.
Frozen tissues of brainstem or pons were obtained from the NICHD Brain and Tissue Bank
for Developmental Disorders at the University of Maryland (Baltimore, MD), and from the
Case Western Reserve University/University Hospitals of Cleveland Brain Bank (Cleveland,
OH). Areas of the frozen brainstem samples containing the substantia nigra were carefully
dissected and were homogenized with Cell Lysis Buffer (Cell Signaling) plus 1 mM
phenylmethanesulfonyl fluoride (Sigma) and Protease Inhibitor Cocktail (Sigma). Equal
amounts of total protein extract were run on a 15% SDS–PAGE gel and transferred to PVDF
(Millipore). Membranes were blocked in 5% milk in TBST for 1 h. Primary antibodies were
incubated overnight in 5% milk in TBST, and washed three times in TBST prior to addition
of the secondary antibody. Secondary antibodies were incubated for 1 h in 5% milk in
TBST, washed three times in TBST and developed using ECL (Pierce). Antibodies used
included anti-actin (Sigma), anti-DJ-1 (Abcam) and anti-Grx1 [20].
Western blot analysis of human blood cells

Author Manuscript

Human blood samples used for this study were collected according to approved IRB
protocols (see patient information Supplemental Table B). PBMCs from 1.5 ml of
cryogenically frozen blood were isolated by lysis of the red blood cells in 10 ml red blood
cell lysis buffer (0.155 M ammonium chloride, 0.01 M potassium bicarbonate, and 0.00013
M EDTA) for 15 min on a rocker. The suspension was spun at 1,500g on a table-top
centrifuge, the supernatant was removed, and 10 ml of red cell lysis buffer was added. This
process was repeated two more times with incubation on the rocker shortened to 5 min each.
The resulting PBMCs were lysed and were analyzed via western blotting in the same
manner as described for the western blot analysis of mouse brain tissue except 35 μg of
lysate was loaded per sample.
Immmunoprecipitation of DJ-1 from mouse brain lysate

Author Manuscript

Whole snap frozen C57BL/6 or FEB mouse brains were placed in 4 ml cell lysis buffer (Cell
Signaling) plus 50 mM iodoacetamide (to block free cysteine-SH). Brains were
mechanically homogenized via mortar and pestle, and then subjected to lysis via sonication
on ice for 2 min, alternating 10 s on 10 s off. Lysate was then spun down at 16,000g at 4°C
in a tabletop centrifuge for 1 hour. The resulting supernatant was divided into aliquots, with
addition of either 50 μl Protein G beads (Pierce) and 5 μg anti-goat IgG (Santa Cruz); or 50
μl Protein G beads and 5 μg anti-DJ-1 (Goat, Abcam). Samples were rotated at 4°C for 48 h,
washed three times in lysis buffer plus 0.25 M NaCl. Laemmeli sample buffer (without
reducing agents) was added and beads were boiled for 10 min. Samples were then run on a
15% non-reducing SDS-PAGE gel, transferred to a PVDF membrane, and probed for
glutathionylation using an anti-glutathione antibody (anti-GSH, Millipore). Membranes
were stripped by incubation in 0.1 M Tris-HCl pH 6.8, 2% SDS, and 0.11 M β-mercapto
Biochemistry. Author manuscript; available in PMC 2016 August 16.
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ethanol at 50°C for 30 min followed by three washes in TBST for 15 min each. Blots were
then probed with rabbit anti-DJ-1 (Cell Signaling) in the same manner as described above.
LC-MS analysis of proteins and peptides

Author Manuscript

Mass spectrometric (MS) analyses were performed using a LTQ Velos dual-pressure linear
ion trap mass spectrometer equipped with an Accela 600 quaternary pump for in-line protein
and peptide high performance liquid chromatography (HPLC) separation and an
electrospray ionization source (Thermo Scientific, Waltham, MA). The electrospray
ionization source was operated in the positive ion mode with the following parameters:
normalized collision energy 35 kV, capillary temperature 300 °C, source voltage 5 kV,
capillary voltage 43 V, and tube lens 105 V. Mass spectra were collected over a 200–2000
m/z range. To record mass spectra of intact proteins, 0.5 μg of DJ-1 or its glutathionylated
form was loaded onto an XBridge BEH300 C4 column (3.5 μm, 2.1 × 50 mm) (Waters,
Milford, MA) and eluted with a linear gradient (5–100%) of acetonitrile in water containing
0.1% formic acid. The gradient was developed over 20 min at a flow rate of 0.25 ml/min..
Masses of the proteins were calculated by deconvolution of intact protein ions using
ProMass for Xcalibur software (Thermo Scientific). The same instrumentation including
column and solvents was employed to separate peptide products of tryptic digestion of DJ-1.
However, to ensure adequate peptide separation the gradient of acetonitrile was developed
over 40 min. The protein tryptic digestion was performed in 50 mM Tris-HCl, pH 7.5, at
37 °C overnight. Products of the reaction were directly analyzed by LC-MS. Peptides were
identified based on a correlation of their tandem-mass spectra (MS/MS) with theoretically
predicted ion fragmentation patterns.

Author Manuscript

The efficiency of protein glutathionylation was assessed by relative quantification of
unmodified DJ-1 in the reaction sample. For this purpose, prior to the tryptic digestion, the
glutathionylated DJ-1 sample was supplemented with an equal amount (12.5 μg) of 15Nlabeled DJ-1. LC-MS analysis of the tryptic peptide mixtures revealed co-eluting native
and 15N-labeled peptides. The relative ion intensities for pairs of native and 15N-labeled
peptides at the same charge state were used to calculate the relative abundance of
unmodified DJ-1 and thus the fraction of glutathionylated protein. Glutathionylation of
cysteine residues were estimated using unmodified 15N DJ-1 as an internal standard.
Quantification of modified tryptic peptides were estimated by subtraction of the peak areas
of the non-modified peptides in the treated 14N-samples from those in the untreated 15Nsamples.
C. elegans strains and maintenance

Author Manuscript

A list of C. elegans strains with their designation, corresponding genotype, and strain
nomenclature is shown in Supplemental Table C. C. elegans strains were maintained on
nematode growth medium (NGM) plates with E. coli OP50 as a bacterial food, as previously
described [6].
Single-worm PCR
Individual worms were placed in PCR tubes containing 10 μl total volume consisting of 1x
OneTaq buffer (New England Biolabs) and 0.5 mg/ml proteinase K (Sigma). Worms were
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frozen on dry ice for 15 min, then lysed via incubation at 65°C for 90 min followed by 95°C
for 30 min. PCR amplifications were performed using OneTaq polymerase following
manufacturer’s instructions (New England Biolabs). Identification of WT and mutant djr-1.2
DNA was accomplished using the following primers (Integrated DNA Technologies),
Forward: 5′-GCAAACTCGAAAGCAGTTGC-3′, Reverse WT: 5′CGTATTGTTCCGGACGTAGC-3′ Reverse knockout: 5′TTTGACCGTGTTCTTTGTCG-3′. Identification of LRRK2 and glrx-10 DNA was
accomplished using the primers described previously [20].
Generation of C. elegans expressing Pdat-1::mCherry or Pdat-1::DJR1.2::mCherry in
dopaminergic neurons

Author Manuscript
Author Manuscript

Plasmids containing Pdat-1::mCherry and Pdat-1::DJR-1.2::mCherry were constructed in the
backbone of the pFxneRFP vector (a generous gift of Dr. S. Mitani, Tokyo Women’s
Hospital, Japan). The Pdat-1 insert was excised from the Pdat-1::pFxneEGFP plasmid [6]
using the KpnI and HindIII sites. The DJR-1.2 open reading frame was PCR amplified from
the DJR-1.2_pDONR201 plasmid (GE) with primers containing the BamHI and Xho1 sites,
Forward 5′-GATATAGGATCCATGGCTGCCCAAAAGAG-3′ and Reverse 5′GTACTACTCGAGTACTTTGCCAAACACAG-3′. The mCherry insert was obtained by
PCR amplification from the pGH8 plasmid (Addgene) with primers containing the NotI and
BglII sites, Forward 5′-ATAATAGCGGCCGCTTAATGGTCTCAAAG-3′ and Reverse 5′GCGCGCGAGATCTACTACTTATACAATTCATCC-3′. Restriction digestion was
performed with appropriate selective enzymes according to the manufacturer’s instructions
(New England Biolabs). PCR products were purified with the QIAquick PCR purification kit
(Qiagen). All DNA fragments were run on 1% agarose gels, followed by extraction with the
QIAquick gel extraction kit (Qiagen). DNA inserts were ligated into pFxneRFP vector at
room temperature for 2.5 h using T4 ligase (New England Biolabs) to generate the Pdat-1::
mCherry and Pdat-1::DJR-1.2::mCherry plasmids. The plasmids were transformed into E.
coli DH5α cells (Life Technologies), propagated, purified on Qiagen miniprep columns, and
verified by DNA sequencing. The DNA constructs were microinjected into C. elegans N2
strain by Knudra Transgenic (Murray, Utah). Stable worm lines with red fluorescent
dopaminergic neurons expressing mCherry (Pdat-1::mCherry) or DJR-1.2 fused with
mCherry (Pdat-1::DJR-1.2::mCherry) were selected, and their genotypes were verified by
PCR.
Basal slowing assay

Author Manuscript

The basal slowing assay was performed as previously described [6]. Briefly, NGM assay
plates were seeded with a ring of E. coli OP50. Age-synchronized worms were transferred to
a non-seeded NGM plate and washed twice in S basal buffer (100 mM NaCl, 10 μg/ml
cholesterol, 50 mM potassium phosphate, pH 6.0). Worms were then transferred to either
seeded or non-seeded assay plates, allowed to recover for 5 min, and their body bends were
recorded in 20 s intervals.
Dopaminergic neuron counting
Approximately 30 age-synchronized adult worms were placed into 200 μl of 10 mM
tetramisole (Sigma) in raised wall four chamber slides (Lab-Tek). GFP neurons were
Biochemistry. Author manuscript; available in PMC 2016 August 16.
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visualized with a Nikon microscope at 20x zoom. Dopaminergic CEP and ADE head
neurons were assessed for degeneration in a blinded fashion, according to published
protocols [ 20]. Neurons with detectable GFP signal were counted as positive, neurons
lacking cell body GFP signal were counted as negative.
Treatment and analysis of SH-SY5Y cells

Author Manuscript

SH-SY5Y cells (ATCC) were grown in OPTI -MEM (Invitrogen) + 10% fetal bovine serum
(Atlanta Biological) at 37 °C with 5% CO2. For H2O2 treatment, cells were treated with
increasing concentrations of H2O2 for 2 h as indicated in the figure legend. For diamide
treatment experiments, cells were pretreated with either 10 μM MG-132 (Sigma) diluted in
DMSO, 1 μM lactacystin (Santa Cruz) diluted in DMSO, 1:200 dilution of cell culture broad
protease inhibitors (Sigma) diluted in DMSO, or DMSO (0.5%) for 7 h. Cells were then
treated with 0.1 mM diamide or PBS for 2 h. All cells were lysed in Cell Lysis Buffer (Cell
Signaling) containing protease inhibitors (Roche) on ice for 15 min with occasional mixing
(Vortex). Lysates were spun down at 4°C for 30 min at 16,000 x g in a table-top centrifuge.
The supernatant (35 μg of protein) was loaded onto a 15% SDS-PAGE gel and western
blotting was completed in the same manner as the mouse midbrain tissue described above.
Validation of glutathionyl mixed disulfide specificity of the anti-GSH Antibody

Author Manuscript

Glutathionylation of proteins can be reversed by addition of disulfide reducing agents. In
order to validate the interpretation of the reactivity of the anti-GSH antibody, anti-DJ-1
beads were used to immunoprecipitate DJ-1 from mouse brains, and the resultant effluent
was processed on a non-reducing SDS-PAGE gel and transferred to a PVDF membrane.
After transfer the blot was blocked in 5% milk for 1h and cut in half. Half of the blot was
incubated with buffer and the other half was incubated with buffer plus 100 mM
dithiothreitol (DTT) for 30 min. The blots were then washed and probed with the anti-GSH
antibody overnight. The blot incubated in buffer alone revealed the prominent band at 45
kDa while the blot incubated in buffer plus DTT failed to show immunoreactivity at 45 kDa
(Supplemental Figure S4). Blots were then stripped and re-probed for DJ-1 confirming the
presence of DJ-1 on both halves of the membrane.
Generation of recombinant DJ-1

Author Manuscript

Recombinant DJ-1 was purified following the protocol described in [23]. Briefly 1.5 L of
BL21(DE3) E. coli containing pET15b-DJ-1 was induced with 1 mM IPTG for 4 h. Cells
were spun down and lysed via lysozyme treatment followed by sonication. Centrifugally
cleared lysate containing 6x-His tagged DJ-1 was bound to Ni2+ His-select resin (Sigma),
washed, eluted with 200 mM imidazole, cleaved with thrombin, and dialyzed overnight.
Uncleaved DJ-1 was removed using a second pass over the Ni2+ column, thrombin was
removed using benzamidine-sepharose resin, and co-purifying nucleic acids were removed
from DJ-1 using a Q-sepharose column. DJ-1 (free of the 6x-His tag) was then concentrated
and snap frozen in liquid nitrogen.
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Recombinant uniformly 15N-labeled DJ-1 was generated as previously described [23].
Briefly, N-terminally 6x-His tagged DJ-1 was expressed from pET15b in BL21(DE3) E coli.
An inoculum of the cells was grown overnight in LB media containing 100 μg/ml ampicillin
at 37°C. 50 ml of this culture was spun down and washed twice in 10 ml of sterile 15NH4Cl
M9 defined media [23] and transferred to 1 L of 15NH4Cl M9 media. These cells were
grown at 37°C and DJ-1 expression was induced by the addition of 0.5 mM IPTG when the
A600 = 0.5. Protein purification was performed as described above. 15N labeling efficiency
was determined using mass spectrometry as described [23] and the incorporation efficiency
was >99%.
RNA isolation and qPCR Methods

Author Manuscript

Midbrain tissue from C57BL/6 and BALBc Grx1−/− mice and age- and sex-matched controls
(when available) was homogenized in 1mL TRIzol (Life Technologies) using a Teflon and
glass mortar and pestle. RNA was isolated according to manufacturer’s instructions.
Resulting RNA was converted to cDNA using SuperScriptII (Invitrogen) according to
manufacturer’s instructions. Park7 (DJ-1) expression (probe Mm00498538_m1) was
analyzed using TaqMan Fast Universal PCR mix (Life Technologies) on the StepOnePlus
machine (Life Technologies) using StepOne v2 software. Park7 expression was normalized
to Gapdh (probe Mm99999915_g1) expression as an internal control.

RESULTS
Grx1 controls DJ-1 protein expression in vivo.

Author Manuscript
Author Manuscript

As reported previously, knockdown of Grx1 via shRNA results in decreased DJ-1 protein
content in the SH-SY5Y [21] and Neuro2A cell lines[ 22], however it is unknown if Grx1
plays a role in mediating DJ-1 protein content in vivo. Midbrain lysates from Grx1−/− and
WT mice in the C57BL/6 background from two independent cohorts were subjected to
western blot analysis, in order to investigate the potential control of DJ-1 by Grx1. Western
blot analysis indicated that Grx1−/− mice have diminished levels of DJ-1 protein compared
to WT controls (Figure 1 A, B). Quantitative PCR was used to measure the mRNA levels of
DJ-1 in the Grx1−/− and WT mice in the C57BL/6 background. No statistical difference was
found in the mRNA levels between the Grx1−/− and WT mice (Supplemental Figure S1A).
We also analyzed DJ-1 content in brain samples (kindly provided by Reiko Matsui, Boston
University) from transgenic mice in which hGRx1 was overexpressed so that total Grx1
content (human plus mouse) was about 2-fold higher relative to WT mice [ 24]. In this case
the DJ-1 content was not different (transgenic vs. WT), suggesting that the normal content of
Grx1 is sufficient to maintain DJ-1 content, at least in the absence of increased oxidative
stress (Supplemental Figure S1B). Notably, we also analyzed midbrain lysates from Grx1−/−
and WT mice in the BALB/c background and these mice did not show a difference in the
DJ-1 protein or mRNA content (Supplemental Figure S1 C, D); thus indicating that
differential genetic expression and/or posttranslational regulation in the BALB/c strain
disconnects the regulatory effect of Grx1 on DJ-1.
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In addition, to investigate whether DJ-1 and Grx1 protein levels correlate in human tissue,
lysates from human peripheral blood mononuclear cells (PBMCs) and post-mortem
midbrain tissue were subjected to western blot analysis. Protein levels of Grx1 and DJ-1
(normalized to actin) showed a significant positive correlation for protein isolated from both
PBMCs (Figures 1 C) and midbrain tissue (Figures 1 D; blots are shown in Supplemental
Figure 2S A, B). Taken together, these data provide in vivo evidence for the first time that
Grx1 influences DJ-1 protein content in the midbrains of mice, and that Grx1 and DJ-1
protein contents are co-variant inhuman tissue s.
Treatment of cells with glutathionylation-inducing agents results in loss of DJ-1 protein

Author Manuscript
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Author Manuscript

As noted, knockdown of Grx1 in model dopaminergic neuronal (Neuro2A) cells via shRNA
resulted in decreased DJ-1 protein, but not mRNA content [22]; however the mechanism by
which this loss of DJ-1 protein occurred remains unclear. We hypothesized that loss of Grx1
results in accumulation of glutathionylated DJ-1 (DJ-1-SSG), which is then rapidly
degraded. In order to test whether agents that promote DJ-1-SSG formation result in loss of
DJ-1 content, SH-SY5Y cells were treated acutely with H2O2, which is known to result in
protein-SSG formation [25, 26]. DJ-1 protein content was selectively diminished in a dose
dependent manner (relative to actin, which is known to be glutathionylated without affecting
its content) (Figure 2 A, B). Since H2O2 can modify cysteine residues to sulfinic and
sulfonic acids in addition to protein-SSG, we wanted to limit the modification to
glutathionylation of DJ-1. Accordingly, cells were treated separately with diamide, an
oxidizing agent characterized to promote selective formation of protein-SSG [27, 28, 29].
Western blot analysis indicated that treatment with diamide also resulted in a significant loss
of DJ-1 protein content compared to untreated controls. (Figure 2 C, D). Notably, the extent
of diminution in DJ-1 protein content (~40%) was similar for both the H2O2- and diamidetreated cells. It was previously reported that loss of DJ-1 content concomitant with
knockdown of Grx1 could be limited by treatment with a cocktail of inhibitors of
proteolysis, consistent with the concept of enhanced degradation [22]. In order to learn
whether loss of DJ-1 after diamide treatment of SH-SY5Y cells displayed the analogous
pattern of non-proteasomal proteolysis as observed in Grx1-dificient Neuro2A cells [22], we
pretreated the SH-SY5Y cells with the proteasome inhibitor MG-132 or with a broad
protease inhibitor (PI) cocktail prior to diamide treatment [22]. Pretreatment with the broad
protease inhibitors, prevented the diamide induced loss of DJ-1 (Figure 2 C, D). Notably,
pretreatment of SH-SY5Y cells with either MG-132 or lactacystin inhibited the proteasome
(as indicated by increased β-catenin content (Figure 2, E, G), but failed to blunt the diamideinduced loss of DJ-1 protein (Figure 2 E, F). These data suggest that treatment of SH-SY5Y
cells with glutathionylation-inducing agents results in DJ-1 degradation in a proteasomeindependent manner.
DJ-1 is glutathionylated in vivo
DJ-1 contains three cysteine residues located at positions 46, 53, and 106. Cysteines 53 and
106 have been reported previously to be oxidatively modified [23, 30], but there is no
evidence for glutathionylation of DJ-1 in a physiological setting. In order to determine if
DJ-1 undergoes glutathionylation in vivo, DJ-1 was immunoprecipitated from whole mouse
brain homogenates and subjected to non-reducing SDS-PAGE and western blot analysis.
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Using an antibody that recognizes glutathionylated moieties (anti-GSH), we observed a
prominent band at approximately 45 kDa (Figure 3 A, arrow). The blot was stripped and reprobed with an anti-DJ-1 antibody, which resulted in a band at the same molecular weight as
recognized by the anti-GSH antibody. (Figure 3 B). The band located at approximately 45
kDa corresponds to the size of the dimeric DJ-1. This suggests that dimeric DJ-1-SSG can
form an intermolecular bond between two DJ-1 monomers either in the cell or while running
through the electric field in the gel. In order to validate that the approximately 45 kDa band
is DJ-1 and not a non-specific band, mouse brain homogenates were immunoprecipitated
with anti-DJ-1 beads to isolate DJ-1, and the sample was split into two aliquots. One aliquot
was reduced with 100 mM dithiothreitol (DTT) and the other was left non-reduced; then the
two samples were analyzed on western blots. The ~45 kDa band appeared in the nonreduced lane, but in the reduced lane a single band was present at approximately 22 kDa,
corresponding to the molecular weight of monomeric DJ-1 (Supplemental Figure S3A). In
addition, western blot analyses with the anti-DJ-1 antibody were performed with DTTtreated lysates of brain samples from WT and DJ-1−/− mice (a kind gift from Vera Bonilha,
Cleveland Clinic Foundation). An immunoreactive band appeared at approximately 22 kDa
as expected for the WT samples; but no band was present for the samples from the DJ-1−/−
mice, documenting the specificity of the anti-DJ-1 antibody (Supplemental Figure 3S B).
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Glutathionylation of proteins can be reversed by disulfide reducing agents. To confirm the
interpretation of the reactivity of the anti-glutathione antibody, DJ- was immunoprecipitated
from mouse brains, run on a non-reducing SDS-PAGE gel and transferred to a PVDF
membrane. After transfer half of the blot was then incubated with 100 mM dithiothreitol
(DTT) for 30 min to reduce glutathionylated cysteines. The blot incubated with DTT lost
immunoreactivty with the anti-GSH antibody(Supplemental Figure 4S). Blots were then
stripped and re-probed for DJ-1 confirming the presence of DJ-1 on both halves of the
membrane. These data show that treatment with DTT results in ablation of reactivity with
the anti-glutathione antibody, consistent with the conclusion that DJ-1 is glutathionylated
within the midbrains of mice. It was also confirmed separately that actin which is known to
be glutathionylated in intact cells[ 31] and has a similar molecular weight (42 kDa) to
dimeric DJ-1 was not detected on the blot of the immunoprecipitated DJ-1 (data not shown).
Preferential glutathionylation of DJ-1 at cysteines 53 and 106
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To further characterize the glutathionylation of DJ-1, 12.5 μg of pure recombinant DJ-1 was
incubated with 5 mM GSH and 1 mM diamide for 30 min and subjected to liquid
chromatography-mass spectrometry (LC-MS) analysis. MS spectra of the untreated (Figure
3 C) and treated (Figure 3 D) intact protein revealed two distinct sets of ions in the treated
sample as compared to untreated DJ-1. The deconvoluted spectrum of untreated DJ-1
revealed the expected protein mass of 20036.3 Da, equal to the theoretical mass of the
polypeptide based on the amino acid sequence. Reaction with GSH and diamide resulted in
increases of 305 and 610 Da in the protein mass to 20341.5 and 20646.7 Da, corresponding
to the additional masses of a single and two glutathionyl moieties covalently attached to
DJ-1 (Figure 3 D).
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To identify the sites of glutathione adduction, the glutathionylation reaction was repeated;
the DJ-1 reaction mixture was dialyzed to remove GSH/diamide, digested with trypsin, and
subjected to tandem MS/MS analysis. The trypsin digests clearly revealed the presence of
two covalently modified peptides DVVIC53PDASLEDAK (m/z = 766.5 [M+2H]+2) and
GLIAAIC106AGPTALLAHEIGFGSK (m/z = 756.4 [M+3H]+3) in the GSH/diamide treated
sample (Figure 4 C–D) as compared to the unmodified DJ-1 (Figure 4 A–B). The identity of
each of the peptides and sites of modification were confirmed by their MS/MS
fragmentation patterns. A 305-Da shift in the b- and y-ion series observed between the
modified and unmodified peptides indicated glutathionylation on the side chains of the
Cys-53 (Figure 4 E) and Cys-106 (Figure 4 F) residues.
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In order to estimate the relative extents of glutathionylation of the different cysteine
residues, “light DJ-1” (14N, natural abundance) was treated with GSH and diamide. An
equimolar amount of “heavy DJ-1” (15N-labeled) was untreated and used as an internal
standard. Both 14N- and 15N-proteins were digested with trypsin, and subjected to LC-MS
analysis (Supplemental Figure 5S, A–E). Quantification of the peak areas for the nonmodified peptides indicated that major glutathionylation occurs at cysteine residues Cys53
and Cys106. The extent of glutathionylation was estimated by subtracting the peak area of
the treated non-modified peptide (14N) from the peak area of the untreated standard peptide
(15N), giving a value for the peak area of the glutathionylated peptide. Accordingly, the
extent of glutathionylation of Cys53 and Cys106 were calculated to be 70 and 77%,
respectively (Table 1). We did find a very minor fraction (~7%) of glutathionylated Cys46
(Table 1), but this was likely due to heterogeneity within the preparation of DJ-1 and/or
unfolding of the protein in solution, as Cys46 is known to be buried in the hydrophobic core
of the protein [ 32]. Taken together, our data show that isolated recombinant DJ-1 is
preferentially glutathionylated at cysteine resides 53 and 106.
Loss of DJ-1 homolog exacerbates LRRK2-mediated dysfunction of dopamine-dependent
movement in C. elegans
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Overexpression of DJ-1 has been shown to mediate dopaminergic neuronal protection
against LRRK2 toxicity in vitro [ 33]. In order to investigate the potential neuroprotective
role of DJ-1 in vivo, we chose to use C. elegans as a model because of the simplicity of the
dopaminergic neuronal system. C. elegans worms contain two distinct homologs to human
DJ-1, DJR-1.1 and DJR-1.2. Two independent groups have reported that DJR-1.1 is
expressed highly in the intestine and not within the head neurons [34, 35]. DJR-1.2, in
contrast, has been reported to be expressed in the dopaminergic neurons of the worms [35].
Therefore, we used DJR-1.2-deficient animals in this study. Genetic crosses were made
between the djr-1.2−/− strain and transgenic animals expressing GFP in the dopaminergic
neurons (used as WT control). In addition, the djr-1.2−/− strain was crossed with lines that
co-express GFP and pathogenic human LRRK2 mutants in the dopaminergic neurons
(G2019S-LRRK2 or R1441C-LRRK2, hereafter referred to as G2019S and R1441C,
respectively) [6]. Crosses were confirmed via PCR genotyping of djr-1.2 and LRRK2(Figure
5A).
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We examined the functional integrity of dopaminergic signaling in the C. elegans lines using
a well-established assay of dopamine-dependent behavior, termed the basal slowing assay
[36]. In agreement with our previous findings, transgenic expression of either G2019S or
R1441C in the dopaminergic neurons of C. elegans resulted in age-dependent loss of
dopamine-dependent movement behavior [6, 20]. Compared to WT, the mutant djr-1.2−/−
worms displayed a late onset loss of dopamine-dependent behavior on adult day 2 (Figure
5B). These data are in agreement with the previous finding that dauer-stage C. elegans
lacking djr-1.2 have a dopamine signaling defect [35]. Moreover, the hybrid lines, both
deficient in DJR-1.2 and expressing G2019S or R1441C, displayed a more robust loss of
dopamine-dependent behavior (Figure 5B). We also examined the morphological integrity of
the GFP labeled-dopaminergic neurons via microscopy in young and aged worms.
Expression of G2019S or R1441C resulted in an age dependent loss of dopaminergic
neurons as previously documented [ 6, 20]. The djr-1.2−/− mutant strain showed decreased
survival of dopaminergic neurons compared to WT on adult day 8 (Figure 5C). Exacerbation
of dopaminergic neuronal loss in the lines lacking DJR-1.2 and expressing LRRK2 mutants
was limited and seen only on adult day 2 in the R1441C; djr-1.2−/− line. These data indicate
that loss of DJR-1.2 in vivo results in diminution of dopamine-dependent behavior,
exacerbation of mutant LRRK2-induced diminution of dopamine-dependent behavior, but
only incomplete dopaminergic degeneration and limited exacerbation of LRRK2 -mediated
dopaminergic degeneration.
Over-expression of DJ-1 homolog partially compensates for the loss of Grx1 in R1441Cmediated neurotoxicity
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We previously found that loss of GLRX-10, the worm homolog of Grx1, exacerbates
LRRK2-mediated dopaminergic dysfunction [20]. Our current data analyzing midbrain
homogenate from Grx1−/− mice indicates that loss of Grx1 results in a decreased protein
content of DJ-1 in vivo(Figure 1 A, B), indicating that regulation of DJ-1 content is
functionally downstream of Grx1. Synthesizing these observations, we hypothesized that the
exacerbation of LRRK2 toxicity by deficiency of the Grx1 homolog in C. elegans [20] is
due, at least in part, to increased glutathionylation and consequent loss of DJ-1. In order to
test if DJ-1 overexpression could rescue the Grx1 deficiency, we generated R1441C;
glrx-10−/− worms specifically expressing DJR-1.2 fused to red fluorescent protein mCherry
(DJR-1.2-mCherry) or mCherry (vector control) in the dopaminergic neurons. The
compound worm lines were confirmed via PCR (Figure 6A) and fluorescence microscopy
(Figure 6B). These worms were subjected to the basal slowing assay to assess their
dopamine-dependent behavior.
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Consistent with the previous report [20], R1441C; glrx-10−/− worms displayed a robust loss
in dopamine-dependent behavior. Expression of the mCherry control in the R1441C;
glrx-10−/− line resulted in no change in basal slowing response compared to its cognate
strain (Figure 6C). Overexpression of DJR-1.2-mCherry in the dopaminergic neurons of the
R1441C; glrx-10−/− worms showed significant improvement in basal slowing response
compared to the R1441C; glrx-10−/− worms expressing the vector control on adult Day 0,
and continued to show apparent but not statistically significant improvement on adult days 1
and 2. These data indicate that expression of DJR-1.2 can partially rescue the pathogenic
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LRRK2 induced dysfunction of dopamine-dependent behavior in C. elegans lacking
GLRX-10.

Discussion
DJ-1 plays an important role in mediating dopaminergic neuronal protection. De -stabilizing
mutations in DJ-1 result in familial PD, and diminished protein content of DJ-1 has been
reported in sporadic cases of PD [ 10, 11]. Furthermore, knockout or knockdown of DJ-1
results in increased susceptibility to toxin-induced dopaminergic cell death in vivo [37, 38].
These studies indicate that protein levels of DJ-1 play an important role in protecting against
dopaminergic degeneration. Hence, deciphering the mechanisms of regulation of DJ-1
protein content represents an important focus of study in PD biology.
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Reversible glutathionylation of proteins is recognized as an important regulatory mechanism
for pathways that mediate cell death/viability [ 39]. For example, the FAS receptor is a
signal transducing receptor that upon activation via Fas-ligand drives cell death through
activation of the death domain. Fas-induced cell death has been shown to be regulated in part
by glutathionylation at cysteine 294 [17]. Treatment of lung fibroblasts with Fas-ligand
resulted in cell death when WT-Fas, but not C294A-Fas was expressed [ 17], suggesting that
glutathionylation of Fas is a pre-requisite for cell death signal transduction. In addition,
glutathionylation of the cell survival kinase Akt has been associated with decreased Akt
activation and reduced cell viability in the human fetal retinal pigment epithelial cells when
challenged with H2O2 [ 40]. Conversely, overexpression of Grx1 resulted in decreased levels
of Akt glutathionylation in response to H2O2 and increased activation of Akt signaling [ 40].
These and other studies demonstrate the functional impact of selective protein
glutathionylation on cell viability under stress conditions.
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Our previous data revealed that Grx1 protein content was decreased in post-mortem samples
of brain tissue from[ 20]. Our current data supports the interpretation that Grx1 regulates
DJ-1 protein content in vivo and that DJ-1 is susceptible to glutathionylation in vitro and in
vivo. Additional data supporting the idea that DJ-1 is regulated by glutathionylation have
been reported. Unlike WT DJ-1, the C106A and C53A mutants of DJ-1 are resistant to
degradation in Neuro2A cells in which Grx1 was knocked down [22]. Our current finding
that cysteine residues 53 and 106 are more readily glutathionylated than cysteine 46 is
consistent with data from the crystal structure of DJ-1 indicating that cysteine 46 is not
solvent accessible and buried within the protein [32]. We hypothesize that glutathionylation
of DJ-1 regulates its protein level in the cell. Consistent with this interpretation, treatment of
SH-SY5Y cells with two known inducers of glutathionylation resulted in decreased DJ-1
protein content. This decrease in DJ-1 protein can be abrogated by pre-treatment with nonspecific protease inhibitors suggesting that the loss of DJ-1 is caused by proteolytic
degradation following glutathionylation. The result is in agreement with previously
published data indicating that loss of Grx1 via shRNA knockdown in Neuro2A cells results
in a loss of DJ-1 protein content [22]. In order to identify which component(s) of the
proteolytic inhibitor cocktail blocked DJ-1 degradation and therefore which pathway(s) is
dysregulated, we treated Neuro2A cells with the individual components and then knocked
down Grx1 via shRNA. As expected, knockdown of Grx1 resulted in a loss of DJ-1 protein
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content; however none of the individual components alone blunted the Grx1 knockdownmediated loss of DJ-1 (Supplemental Figure 7S, A–F). These data suggest a complex
mechanism of degradation likely involving multiple enzymes contributing to regulation of
DJ-1 degradation.
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In order to test whether DJ-1 plays a functional role in regulating dopaminergic viability in
concert with Grx1in vivo we used C. elegans as a model system. We previously found that
C. elegans lacking GLRX -10, the Grx1 homolog, displayed an exacerbation of the
neurodegenerative phenotype in both familial and sporadic models of PD [ 20]. Our
observation of decreased levels of DJ-1 in Grx1−/− mice led us to hypothesize that decreased
DJ-1 could be at least partly responsible for the more toxic PD-like phenotype in the C.
elegans lines lacking GLRX-10. Protein content of DJ-1 within the glrx-10−/− worms was
not determined because the antibodies for human DJ-1 failed to specifically recognize C.
elegans DJR-1.2 (data not shown). As an alternative approach to test if an elevated content
of DJ-1 could compensate for the loss of GLRX-10 in C. elegans, DJR-1.2 was specifically
expressed in the dopaminergic neurons of R1441C-LRRK2; glrx10−/− worms. Using the
well-established basal slowing assay to determine integrity of dopamine-dependent behavior,
we found that expression of DJR-1.2 could partially compensate for the loss of GLRX-10.
Indeed, the protective effect of DJ-1 appears to occur early in the life of the worm and then
fades in adulthood (Figure 6C). Fluorescence microscopic analysis was conducted on adult
days 0 and 2 to assess levels of mCherry in control worms or in worms expressing
exogenous mCherry-tagged DJ-1 protein. Quantification of mCherry/GFP intensity showed
no difference in the expression of exogenous mCherry in the control lines on adult days 0
and 2 as expected (Supplemental Figure S6, left panel). Notably there was also no change in
the mCherry/GFP ratio in the DJ-1:mCherry worms (Supplemental Figure S6, right),
indicating that diminution of DJ-1 mediated protection with age is not due to a loss of the
exogenous DJ-1 protein. These data suggest several alternative hypotheses for why the effect
of the overexpressed DJ-1 fades with time, including (a) the levels of exogenous DJ-1 fail to
sustain protection due to an increased burden of ROS over time in these LRRK2-expressing
worms: (b) DJ-1 is functionally inactivated in the worms due to increased ROS; and (c) the
DJ-1 mediated dopaminergic neuronal protection involves co-factors that may be deactivated
by glutathionylation in the absence of the Grx1 homolog. One or more of these hypotheses
may be supported by previous findings. For example, it has been reported that pathogenic
LRRK2 drives increased ROS expression in vitro [ 41]; DJ-1 has been reported to exist in a
(possibly inactive) sulfonic acid state after oxidative challenge [42]; the glutathionylated
protein database [ 43] reports that the DJ-1 binding partner thioredoxin-1 can be
glutathionylated. Taken together these observations provide a plausible explanation for the
transient protective effect of elevation of DJR-1.2 content, contributing some compensation
for loss of the Grx1 homolog and some protection against mutant LRRK2-mediated toxicity
in vivo.
Although DJ-1 provides some protection against exacerbation of LRRK2 toxicity by
glutaredoxin deficiency, the lack of complete rescue indicates that other protein(s) also likely
play a role in mediating Grx1 neuronal protection. For example, Akt1 is a well-established
survival kinase that has been shown to play neuroprotective roles in a variety of contexts
including PD [ 44]. Notably, the G2019S- and R1441C-LRRK2 mutants showed a decreased
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ability to phosphorylate and activate Akt1 in vitro, suggesting that pathogenic mutations of
LRRK2 drive toxicity at least in part through loss of a critical cell survival signaling
mechanisms involving Akt [ 45]. Proper activation/regulation of Akt is critical for Akt
mediated protection. Considering the context of Grx1 deficiency, it is important to note that
Akt1 has been reported in other contexts to be regulated both directly [40] and likely
indirectly [46] through reversible protein glutathionylation. Thus, treatment of human retinal
pigment epithelial cells with H2O2 resulted in Akt1 glutathionylation, impaired
phosphorylation of Akt1, and cell death [40]. Over-expression of Grx1 resulted in decreased
levels of glutathionylated Akt1, normalized phosphorylation/activation of Akt1, and
increased cell viability when challenged with H2O2 [40]. These data indicate that
glutathionylation of Akt itself or of regulators of Akt may interfere with its cell-survival
activity. In particular, Akt1 is positively regulated through phosphorylation by the upstream
kinase PKC [47], and PKC itself appears to be negatively regulated by glutathionylation
[43]. Thus, purified recombinant PKC treated with diamide and 35S-GSH was found to be
glutathionylated and inactivated. Furthermore, glutathionylation of intracellular PKC was
confirmed by documenting DTT-reversible incorporation of 35S-radioactivity into PKC that
was immunoprecipitated from diamide-treated NIH3T3 cells in which GSH had been
radiolabeled [46]. These data suggest that glutathionylation and concomitant inactivation of
PKC would decrease Akt1 phosphorylation and result in an impaired ability to respond to
stress. Taken all together, loss of Grx1within dopaminergic neurons besides affecting cell
viability through diminution of DJ-1 may also result in an impaired stress response due to
hyper-glutathionylation of PKC and Akt. The increased glutathionylation and consequent
inactivation of DJ-1 and the Akt pathway may combine to explain the exacerbated toxicity
seen when the Grx1 homolog is genetically ablated in models of familial and sporadic PD.
[ 20]. Hence, further studies are warranted to examine the synergistic impact of
dysregulation of glutathionylation on neuronal cell survival mechanisms involving DJ-1 and
Akt.
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Therapeutic advancement in the general PD population has not changed greatly since the
introduction of levodopa as the primary therapy for PD in the 1960’s. Currently there are no
therapeutic approaches available to slow the progression of dopaminergic degeneration. The
ideal intervention would slow or even reverse the degeneration of dopaminergic neurons by
targeting a dysregulated pathway common to both familial and sporadic PD. Although
familial mutations represent only approximately 10 percent of all PD cases, posttranslational modifications mimicking the functional consequences of the genetic mutations
may play a role in the development of sporadic PD. In our previous study post-mortem PD
brain tissue was found to have diminished levels of Grx1 [20], supporting the possibility that
glutathionylation of key proteins involved in PD development/progression may contribute to
PD pathogenicity. Our current data are consistent with the idea that glutathionylation of DJ-1
results in its degradation leading to decreased protein levels. This loss of DJ-1 protein
mimics the outcome of the pathogenic L166P mutation that results in reduced steady-state
levels of DJ-1 [ 48]. A search of the database dbGSH reveals that several other proteins
implicated in the etiology of PD are susceptible to glutathionylation [43]. These proteins
include VPS35, UCH-L1, and EIF4G1. Although these proteins can be glutathionylated, it is
unclear if glutathionylation affects the function of these proteins in an analogous manner to
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pathogenic mutations, so further study is warranted. Nevertheless, the potential impact of
deficient Grx1 on glutathionylation status and function of proteins implicated in PD suggests
that pharmacologically increasing Grx1 activity in neurons may decrease dopaminergic
toxicity by regulating not only DJ-1 protein content, but also other downstream targets that
are altered via glutathionylation.
Statistical analysis
Statistical analyses of the reported data, as noted in the figure legends, were performed using
ANOVA followed by Tukey’s post hoc test, Student’s t-Test, or one-way linear regression.
All statistical analyses were run using Microsoft Excel or GraphPad Prism.
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ATCC

American Type Culture Collection

C. elegans

Caenorhabditis elegans

Grx1

Glutaredoxin 1

GSH

Glutathione

GSSG

Glutathione disulfide

Protein-SSG

Glutathionylated protein

HPLC

High performance liquid chromatography
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PBMCs

Human peripheral blood mononuclear cells

DJ-1-SSG

Glutathionylated DJ-1

LRRK2

Leucine Rich Repeat Kinase 2

LC-MS

Liquid chromatography-mass spectrometry

m/z

Mass/charge ratio

MS

Mass spectrometry (mass spectrometric)

NGM

Nematode growth media

PD

Parkinson’s disease

TBST

Tris-buffered saline with 0.05% Tween-20
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Figure 1. DJ-1 protein content is regulated by Grx1 in vivo
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(A) Western blot analyses of midbrain homogenates from WT and Grx1−/− mice probed with
anti-Grx1, anti-DJ-1, and anti-actin antibodies, respectively. (B) Quantification of DJ-1
protein content (normalized to actin) in the lysates of midbrain samples from WT and
Grx1−/− mice; n = 6 independent WT and Grx1−/− mice/*p<0.05. Statistical analysis was
completed using Student’s T-test. Error bars represent SEM. (C) Positive correlation
between the protein contents of DJ-1 and Grx1 (normalized to actin) in human PBMCs; n =
14 independent biological samples/p<0.01, R2=0.54. Statistical analysis was completed
using a one-way linear regression test. (D) Positive correlation between the contents of the
DJ-1 and Grx1 proteins (normalized to actin) in lysates of human post mortem midbrain
tissue; n = 14 independent biological samples/p<0.01, R2=0.63. Statistical analysis was
completed using a one-way linear regression test.
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Figure 2. DJ-1 protein content is diminished after treatment with glutathionylation-inducing
agents

Author Manuscript

(A) Representative western blot analysis of lysates from SH-SY5Y cells treated with
increasing concentrations of H2O2. The blot was partitioned and probed with anti-DJ-1 or
anti-actin, respectively. (B) Quantification of normalized DJ-1 content after H2O2 treatment;
n = 8 independent biological replicates. (C) Representative western blot analysis of lysates
from SH-SY5Y cells pretreated with DMSO, or a broad protease inhibitor cocktail (PI, see
Methods); then treated with PBS or 0.1 mM diamide. The blot was partitioned and probed
with anti-DJ-1 or anti-actin, respectively. Lane 1, DMSO + PBS; lane 2, DMSO + diamide;
lane 3, PI + PBS; lane 4, PI + diamide. (D) Quantification of normalized DJ-1 content after
diamide and PI treatments; n=8 independent biological replicates. (E) Representative
western blot analysis of lysates from SH-SY5Y cells pretreated with DMSO, MG-132, or
lactacystin; then treated with PBS or 0.1 mM diamide. The blot was partitioned and probed
with anti-β-catenin, anti-DJ-1, and anti-actin, respectively. (F) Quantification of DJ-1
protein content (normalized to actin); n = 8 independent biological replicates. Statistical
analyses for quantifications shown in (B), (D), and (F) were completed using ANOVA
followed by Tukey’s post hoc test. Error bars on quantification for (B), (D), and (F)
represent SEM.
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Figure 3. DJ-1 is glutathionylated in vivo and in vitro

Author Manuscript

(A) Representative western blot analysis of immunopreciptated DJ-1 from mouse brain
homogenate probed with anti-glutathione (GSH) antibody. Replicate analyses of four
independent biological samples gave similar results. Arrow denotes a band of
immunoreactivity at approximately 45 kDa. (B) Immunopreciptated DJ-1 recognized by
anti-DJ-1 antibody. The blot shown in (A) was stripped and re-probed with anti-DJ-1
antibody. Again, this was replicated with the four different samples. Arrow denotes a band
of immunoreactivity at approximately 45 kDa. Overlay of the films shown in panels A and B
documented coincidence of the 45 kDa band, representing glutathionylated DJ-1. (C)
Electrospray ionization mass spectrum of intact recombinant DJ-1. The mass spectrum
shows a distribution of charged states (+11 to +28) for intact DJ-1 protein. Deconvolution of
the spectrum reveals a protein mass of 20036.3 Da, which is identical to the theoretical mass
of recombinant DJ-1. (D) Electrospray ionization mass spectrum of glutathionylated DJ-1.
Incubation of DJ-1 protein with 5 mM GSH and 1 mM diamide led to an increase in protein
mass of 305-Da (blue ion series, deconvoluted mass = 20341.5 Da) or 610-Da (red ions
series, deconvoluted mass = 20646.7 Da), corresponding to covalent modification of DJ-1
with one or two glutathione moieties, respectively.
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Figure 4.
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Identification of the glutathionylation sites of DJ-1 by tandem mass spectrometry. Selective
Ion chromatographs of tryptic digest of DJ-1 treated with 5 mM GSH and 1 mM diamide
revealed two Cys containing peptides (C) DVVIC53PDASLEDAK (m/z = 766.5 [M+2H]+2)
and (D) GLIAAIC106AGPTALLAHEIGFGSK (m/z = 1258.2 [M+2H]+2), with
corresponding masses increased by 305-Da as compared to the untreated sample shown in
(A) and (B). (E) and (F): MS/MS fragmentation pattern of these peptides identifies Cys53
and Cys106 residues as the sites of glutathionylation. According to Biemann nomenclature,
the series of b and y ions are identified in the mass fragmentograms and in the diagrams of
the Cys-containing peptides at the top of panels E and F. For example, the site of
glutathionylation at Cys-53 is identified by the loss of 408 mass units for the y9 ion versus
the y10 ion, corresponding to the loss of the cysteinylglutathione moiety.

Biochemistry. Author manuscript; available in PMC 2016 August 16.

Johnson et al.

Page 25

Author Manuscript
Author Manuscript
Author Manuscript

Figure 5. Loss of DJR-1.2 induces PD phenotypes in C. elegans, exacerbates mutant LRRK2mediated impairment of dopamine dependent behavior, but does not consistently exacerbate
mutant LRRK2-mediated dopaminergic neurodegeneration
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(A) Representative PCR analysis of LRRK2 (upper panel) and WT djr-1.2 or mutant djr-1.2
DNA (lower panel) in C. elegans lines. Primers of djr-1.2 were designed to generate two
distinct PCR products depending on the inclusion (upper band) or exclusion (lower band) of
the first exon of djr-1.2 in the C. elegans lines. (B) Basal slowing data demonstrating that
loss of DJR-1.2 results in dysfunction of dopamine-dependent movement, and exacerbates
R1441C- and G2019S-mediated dysfunction of dopamine-dependent movement; *p<0.05,
comparing control to djr-1.2−/−; #p<0.05, comparing R1441C to R1441C;
djr-1.2−/−; &p<0.05, comparing G2019S to G2019S; djr-1.2−/−. (C) Dopaminergic
degeneration data demonstrating that loss of DJR-1.2 results in late onset degeneration, but
does not exacerbate mutant LRRK2-mediated degeneration consistently. ^p<0.05 comparing
control to djr-1.2−/−, $p<0.05 comparing R1441C to R1441C; djr-1.2−/−. For (B) and (C)
error bars represent SEM. n = 3 independent groups of worms for all days, ~10 worms (B)
or ~30 worms (C) per genotype per experiment. Statistical analysis was completed using
one-way ANOVA followed by Tukey’s post-hoc test. Statistical comparisons between WT
and LRRK2 expressing lines recapitulated previously published experimental data [20], and
were not included to simplify the figure.
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Figure 6. Over-expression of DJR-1.2 partially compensates for the loss of GLRX-10
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(A) PCR analysis of LRRK2 (upper panel), WT or mutant glrx-10 DNA (middle panel), and
coding DNA sequence (CDS) of djr-1.2 (lower panel) indicating the generation of R1441C;
glrx-10−/−; vector (mCherry) and R1441C; glrx-10−/−; DJR-1.2-mCherry expressing C.
elegans lines. (B) Fluorescent images of the head region of the newly generated C. elegans
depicting the expression of Pdat-1::mCherry and Pdat-1::DJR-1.2:mCherry in the
dopaminergic neurons. Expression of GFP tagged dopaminergic neurons co-localize with
expression of both Pdat-1::mCherry and Pdat-1::DJR-1.2::mCherry indicating dopaminergic
expression of mCherry and DJR-1.2-mCherry, respectively. (C) Basal slowing data
demonstrating that over-expression of DJR-1.2 partially recues the LRRK2-R1441C
mediated dysfunction of dopamine-dependent movement in the glrx-10−/− background.
*p<0.05 compared to R1441C; glrx-10−/−; vector. Error bars represent SEM. n = 3
independent groups of worms for all days, 10 worms per genotype per experiment.
Statistical analysis was completed using one way ANOVA followed by Tukey’s post-hoc
test.
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Supplemental Figure Legends
S1. QPCR and Western blot data for transgenic Grx1 and WT mice. (A) QPCR analysis of DJ-1 mRNA from
WT and Grx1-/- mice in the C57BL/6 background. N=3 mice per group, no statistical difference via Student’s TTest. (B) Western blot analysis of transgenic mice over-expressing hGrx1; tissue probed with anti-Grx1, antiDJ-1, and anti-actin antibodies, respectively. (C) Western blot analysis of WT and Grx1-/- mice in the BALB/c
background; tissue probed with anti-Grx1, anti-DJ-1, and anti-actin antibodies, respectively. N=3 mice per
group. (D) QPCR analysis of DJ-1 mRNA from WT and Grx1-/- mice in the BALB/c background. N=3 mice per
group, no statistical difference via Student’s T-Test.
S2. Western blot data for human samples. (A) Western blot analysis of samples extracted from human PBMCs
probed with anti-Grx1, anti-DJ-1, and anti-actin antibodies, respectively; n= 14 independent biological samples.
(B) Western blot analysis of samples extracted from human midbrain tissue probed with anti-Grx1, anti-DJ-1,
and anti-actin antibodies, respectively; n = 14 independent biological samples.
S3. Validation of the DJ-1 antibody. (A) Western blot analysis of immunopreciptated DJ-1. Left lane, reduced
(+ DTT); right lane, non-reduced ( - DTT). (B) Western blot analysis of brain tissue homogenates from DJ-1-/and WT mice treated with DTT and probed with anti-DJ-1, and anti-actin antibodies, respectively. N=2 mice
per genotype.
S4. Validation of the DJ-1 glutathionylation. DJ-1 was immunoprecipitated from mouse brain lysate, run under
non-reducing conditions and transferred to PVDF membrane. Half of the blot was soaked in TBST buffer without DTT, and the other half was soaked in TBST buffer containing 100 mM DTT. The blots then were probed
with the anti-GSH antibody, stripped, and re-probed with the anti-DJ-1 antibody for confirmation of DJ-1 protein. Loss of anti-GSH signal in the presence of DTT indicates that the disulfide reducing agent ablates the antiGSH signal consistent with loss of the glutathionyl mixed disulfide adduct of DJ-1 (A) Western blot analysis of
the membrane incubated with TBST (B) Western blot analysis of membrane incubated in TBST and DTT. Arrows indicate the ~45 kDa immunoreactive band.
S5. Quantification of glutathionylated DJ-1 peptides. (A) and (B) represent selective ion chromatograms for two
cysteine-containing DJ-1 peptides unmodified by glutathionylation; (C) and (D) correspond to the same peptides obtained from 15N-labeled DJ-1, serving as internal standards. Areas under the ion intensity peaks, colored
in gray were used to calculate ratios between 15N-enriched and natural abundance peptides to determine the
fraction of each peptide covalently modified by glutathione. (E) and (F) represent MS spectra averaged at the
peak of ion intensities for DVVIC53PDASLEDAK and GLIAAIC106AGPTALLAHEIGFGSK peptides,
respectively. Ions and their isotopic distribution for both 15N-enriched (blue) and natural abundance (black)
peptides are shown.
S6. Quantification of mCherry and DJR-1.2:mCherry protein content in the dopaminergic neurons of C. elegans
by fluorescence microscopy. Quantification indicates that content of mCherry and DJ-1:mCherry protein (relative to GFP expression specifically in the dopaminergic neurons) are equivalent and do not change over time.
S7. Quantification of relative DJ-1 protein content in Neuro-2A cells transfected with scRNA/Grx1 shRNA and
treated with individual protease inhibitors from the protease inhibitor cocktail. Neuro-2A cells transfected with
scRNA/Grx1 shRNA were treated with individual protease inhibitors or with DMSO (D; vehicle) for 48 hr with
fresh medium containing inhibitor or vehicle replaced every 12 hr. Panels show representative Western blots of
DJ-1 along with respective loading control β-tubulin (Tub) and densitometric analyses. The inhibitors added
with scRNA/shRNA are: (A) 52 µM 4-(2-aminoethyl) benzenesulfonyl fluoride, (Ae), (B) 40 nM aprotinin,
(Ap), (C) 2 µM bestatin (Be), (D) 700 nM E-64 (E64), (E) 1 µM leupeptin (Le) and (F) 750 nM pepstatin A
(Pe). All data were analyzed using one-way ANOVA followed by Student-Newman-Keuls test to determine
significant differences with * representing p < 0.05. n = 3-6 independent samples in each experimental group.
None of the individual protease inhibitors tested alone afforded protection of DJ-1 from degradation, unlike the
complete cocktail.
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A

Patient information for PBMC analysis

Pa+ent	
  Refernce	
  #	
  
Age	
  
Sex	
  
Diagnosis	
  
137	
  
62	
  
F	
  
PD	
  
219	
  
67	
  
M	
  
PD	
  
228	
  
77	
  
M	
  
PD	
  
236	
  
67	
  
M	
  
PD	
  
254	
  
65	
  
M	
  
PD	
  
256	
  
74	
  
M	
  
PD	
  
257	
  
80	
  
M	
  
PD	
  
260	
  
46	
  
M	
  
PD	
  
262	
  
73	
  
M	
  
PD	
  
264	
  
57	
  
M	
  
PD	
  
266	
  
70	
  
M	
  
PD	
  
268	
  
64	
  
M	
  
PD	
  
270	
  
75	
  
M	
  
PD	
  
271	
  
58	
  
F	
  
PD	
  
Cases	
  used	
  for	
  Western	
  blot	
  analysis	
  from	
  PBMC	
  lysate.	
  	
  

B	
  

Patient information for brain lysate analysis

Pa+ent	
  
Refernce	
  #	
  
Sex	
  
Age	
  
Diagnosis	
  
P08-‐40	
  
F	
  
86	
  
PD	
  
P08-‐41	
  
F	
  
83	
  
PD	
  
P08-‐42	
  
M	
  
75	
  
PD	
  
P08-‐43	
  
M	
  
71	
  
PD	
  
P08-‐34	
  
M	
  
51	
  
Control	
  
P08-‐35	
  
M	
  
89	
  
Control	
  
P08-‐36	
  
F	
  
86	
  
Control	
  
P08-‐37	
  
M	
  
73	
  
Control	
  
P08-‐38	
  
M	
  
69	
  
Control	
  
PD1	
  
M	
  
77	
  
PD	
  
PD2	
  
F	
  
49	
  
PD	
  
PD3	
  
F	
  
61	
  
PD	
  
PD4	
  
M	
  
73	
  
PD	
  
Cases	
  used	
  for	
  Western	
  blot	
  analysis	
  from	
  post	
  mortem	
  midbrain	
  +ssue.	
  	
  

C	
  
Designation
Control (GFP)
R1441C
G2019S
R1441C; glrx-10−/−
djr-1.2-/R1441C; djr-1.2-/G2019S; djr-1.2-/R1441C; glrx-10-/-; DJR-1.2
R1441C; glrx-10-/-; Vector

Genotype
lin-15(n765ts)X; cwrIs730[Pdat-1::GFP, lin-15(+)]
lin-15(n765ts)X; cwrIs851[Pdat-1::GFP, Pdat-1::LRRK2(R1441C), lin-15(+)]
lin-15(n765ts)X; cwrIs856[Pdat-1::GFP, Pdat-1::LRRK2(G2019S), lin-15(+)]
glrx-10(tm4634)I; cwrIs851
djr-1.2(tm1348)V
djr-1.2(tm1348)V; cwrIs851
djr-1.2(tm1348)V; cwrIs856
glrx-10(tm4634)I; cwrIs851; cwrEx20[Pdat-1::DJR-1.2::mCherry]
glrx-10(tm4634)I; cwrIs851; cwrEx22[Pdat-1::mCherry]
Caenorhabdi+s	
  elegans	
  strains	
  used	
  in	
  this	
  study	
  	
  

Strain
SGC730
SGC851
SGC856
SGC302
tm1346
SGC10
SGC11
SGC20
SGC22

Reference
[6]
[6]
[6]
[20]
NBP
This study
This study
This study
This Study

NBP: National Bioresource Project (Japan)

